Houston's Dr. Stanislaw R. Burzynski Receives Cross of Merit Award from the Polish Government for Pioneering Research in Cancer Treatment.HOUSTON -- On Oct. 23, 2004, the Polish American Congress The Polish American Congress is a U.S. umbrella organisation, representing, as of 2007 [1], a group of 18 Polish American organizations. Its membership is composed of fraternal, educational, veteran, religious, cultural, social, business, and political organizations, as and the Polish community will celebrate the 150th Anniversary of the founding of the first permanent Polish settlement in America at Panna Maria, Texas Panna Maria (Polish for Miss Mary) is a small town in Karnes County, Texas, USA. It is the oldest Silesian settlement in the United States. A Franciscan missionary, Father Leopold Moczygemba, started recruiting Silesian immigrants in 1852, and the town was settled on , December, 1854. A Gala Awards Banquet will be held at the Marriott Hotel-Sugar Land on Saturday, Oct. 23 (6:30 p.m. reception, 8:00 p.m. dinner.) This will be the culmination of a week-long celebration in Houston, including an art exhibit, symphony concert and educational forum highlighting Polish contributions to American culture and society. The awards ceremony at the Gala Banquet on Oct. 23 will include a presentation of the Polish Cross of Merit There are hundreds of decorations that bear the name "Cross of Merit". As a rule a cross of merit is higher than a medal but not as esteemed as the grade of Knight in an order of merit. to Houston's Stanislaw R. Burzynski, M.D., Ph.D. and his wife Barbara Burzynski, M.D. in recognition of their pioneering research and contributions to the treatment of deadly cancers. The Burzynski Research Institute, which they founded in 1983 in Stafford, Texas (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BZYR), has recently received Orphan Drug Designation from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for its primary cancer medications (A10 and AS2-1) for treating patients with brain stem gliomas Background: Brainstem gliomas are tumors that occur in the region of the brain referred to as the brain stem, which is the area between the aqueduct of Sylvius and the fourth ventricle. , the deadliest of brain tumors, for which there is currently no effective long-term therapy. Other Polish-American Texans will receive awards for their contributions in music, education and broadcasting. Distinguished guests at the Gala Banquet will include Lech Walesa, former President of the Republic of Poland The President of the Republic of Poland (Polish: Prezydent Rzeczypospolitej Polskiej) is the Polish Head of State. He or she is directly elected by the people to serve a term of five years. He can be reelected only once. , His Excellency Przemyslaw Grudzinski, Ambassador of the Republic of Poland, Honorable Krystyna Biernacik-Tokarski, Polish Consul General in Los Angeles, Honorable Zbigniew Wojciechowski, M.D., Honorary Consul of the Republic of Poland in Houston, the Most Reverend Bishop John Yanta, Bishop of Amarillo and Marian L. Kruzel, President of the Polish American Congress-Texas District. Additional information about the Polish American Congress, the 150th Anniversary Celebration and the distinguished guests attending can be obtained by calling Marian Kruzel at 281-561-6304 or Zbigniew Wojciechowski at 281-565-1507. Burzynski Research Institute is a biopharmaceutical company committed to developing medicines for serious and life threatening diseases from genomics and naturally occurring compounds. Research and development efforts are focused on antineoplastons, autoimmune disease and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. BRI See ISDN. BRI - Basic Rate Interface cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for Antineoplastons A10 and AS2-1. Receiving orphan drug designation does not increase the likelihood of eventual regulatory approval for a product candidate. BRI does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion